7月19日到26日，全球医药市场共签署了13项授权和合作协议。中国医药市场上，共签署了4项交易，包括3项对外授权协议和1项国内协议。值得关注的交易是三迭纪与BioNTech签署了一项价值12.1亿美元的授权协议，包括1000万美元的首付款。
在全球范围内，共有9项授权和合作协议最终确定。本周的亮点交易是Dren Bio与诺华之间达成双特异性抗体资产交易，总价值30亿美元，首付款1.5亿美元。另一项重要交易是Day One Biopharma与Ipsen就tovorafenib达成的授权和投资协议，总计4.61亿美元，首付款为1.11亿美元。
From July 19 to 26, a total of 13 licensing and cooperation deals were signed globally. In the Chinese biotech industry, there were 3 out-licensing deals and 1 domestic deal. Notably, Triastek and BioNTech signed a license agreement valued at $1.21 billion, including a $10 million upfront payment.
Globally, nine licensing and cooperation agreements were finalized. The highlight deal of the week was between Dren Bio and Novartis, involving bispecific antibodies, with a total value of $3 billion and an upfront payment of $150 million. Another significant deal was the license and investment agreement between Day One Biopharma and Ipsen for tovorafenib, totaling $461 million with an upfront payment of $111 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
